Position in LYEL
as of Mar 31, 2026
· filed Apr 15, 2026
Position Value
$9,428
-$3,376 QoQ
Shares Held
470
+13.0% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LYEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026GF FUND MANAGEMENT CO. LTD. holds $82,411,911 across 209 Biotechnology names. LYEL ranks #162 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
64,591 | $28,842,465 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
28,281 | $21,851,031 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
30,041 | $9,939,665 | |
| 4 | INSM |
INSMED Inc
|
48,496 | $7,930,065 | |
| 5 | INCY |
Incyte Corp
|
8,742 | $822,797 | |
| 6 | ARGX |
Argenx SE
|
653 | $476,853 | |
| 7 | RPRX |
Royalty Pharma plc
|
9,596 | $460,320 | |
| 8 | MRNA |
Moderna, Inc.
|
8,775 | $445,770 |
All Filings in LYEL
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $9,428 | 470 | Shares | Sole | 2026-04-15 | |
| 2025-12-31 | $12,804 | 416 | Shares | Sole | 2026-01-27 | |
| 2025-09-30 | $6,707 | 413 | Shares | Sole | 2025-11-07 | |
| No filing history on record for this holder in this stock. | ||||||